Alongside HOXC6, whereby gene silencing was seen to increase CRC cell sensitivity to irinotecan [66], a recent study has shown that knockdown of FOXD1, another transcription factor also of higher expression in RCRC [53, 54], increases sensitivity to oxaliplatin both in vitro and in vivo [71]. The gene discussed is FOXD1; the disease is colorectal carcinoma.